The short answer
High-dose vitamin E supplements deserve a bleeding-focused precaution with aspirin because direct platelet studies and NIH ODS cautions raise concern. The exact added major-bleeding risk has not been quantified. Food sources and ordinary dietary intake are not the same as high-dose capsules, and neither a blanket avoidance rule nor a protective dosing interval has been established.
What this answer covers
Distinguishes food from high-dose vitamin E supplements and preserves dose and formulation uncertainty. Vitamin E is not recommended here for cardiovascular prevention.
- Supplement or preparation
- Vitamin E
- Medication ingredient
- aspirin
High-dose capsules and food are not interchangeable
Vitamin E from food should not automatically be treated like a high-dose capsule. NIH ODS describes different natural and synthetic alpha-tocopherol forms and different IU-to-milligram relationships. Many vitamin-E-only supplements contain amounts far above ordinary dietary intake. The reported 0.4 g (400 IU)/day notation in one older trial is preserved as published, not converted into a general dose equivalence.
Why there is a precaution
In a six-week volunteer study, vitamin E plus aspirin was associated with lower platelet adhesion to collagen, while aspirin alone did not affect that measure. Platelet testing is not the same as a clinical major-bleeding outcome, but it gives a reason to take high-dose supplement use seriously when aspirin is already part of a bleeding-risk picture.
The clinical bleeding estimate remains uncertain
In the 100-person preliminary TIA study, hemorrhagic stroke incidence did not differ significantly, although both events occurred in vitamin E recipients. In the 4,495-person Primary Prevention Project, severe bleeding was 1.1% with aspirin versus 0.3% with no aspirin. That was an aspirin main effect, not an estimate of bleeding added by vitamin E.
No prevention or timing promise
The Primary Prevention Project found no vitamin E effect on its prespecified endpoints, so these older studies do not support taking vitamin E for cardiovascular prevention. No source here proves that every aspirin user must avoid vitamin E or that spacing doses reduces risk. Discuss a high-dose capsule, its form, and other bleeding-risk medicines with a clinician or pharmacist instead of relying on a generic cutoff or interval.
Evidence and practical considerations
Side effects & toxicity
High-dose vitamin E supplements warrant a bleeding-focused precaution with aspirin, but the exact added major-bleeding risk is not quantified.
- Exact scope
- Vitamin E supplements, especially high-dose capsules. Food intake is distinct; natural and synthetic forms differ. with Oral aspirin; direct studies used 300 mg every other day, an incompletely specified combination regimen, or 100 mg/day in factorial main-effect reporting.
- Medication form and route
- oral aspirin; oral vitamin E supplements as reported
- Timing or duration
- Six weeks in platelet volunteers, two years in the preliminary TIA trial, and mean 3.6 years in PPP.
What remains uncertain
- No direct precise major-bleeding increment; platelet outcomes are surrogates; PPP gives aspirin main effects only.
Factors that may matter: supplement dose and form; other bleeding-risk medicines; history of bleeding.
Read the supporting source summaries
Source 1: controlled volunteer study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 20 men and 27 women; three experimental groups of 12 and control group of 11.
Vitamin E plus aspirin was associated with highly significant lower platelet adhesion to collagen; aspirin alone did not affect that adhesion measure.
How this applies: Direct co-use platelet-function evidence, not a quantified clinical bleeding outcome.
Allocation and combination-group schedule incompletely described; surrogate platelet outcomes; no clinical bleeding estimate.
Source 2: double-blind randomized study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 100 patients with transient ischemic attacks, minor strokes, or residual ischemic neurologic deficits.
No significant difference in hemorrhagic-stroke incidence; both hemorrhagic strokes occurred in vitamin E recipients. Abstract calls results preliminary.
How this applies: Direct co-use clinical context but insufficient to quantify added bleeding risk or recommend vitamin E for prevention.
No numeric bleeding effect, ambiguous vitamin E mass/activity notation and form, and no validated general conversion from the reported notation.
Source 3: open randomized 2x2 factorial trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 4,495 people at cardiovascular risk; mean age 64.4 years.
Severe bleeding was 1.1% with aspirin versus 0.3% with no aspirin; vitamin E had no effect on prespecified endpoints. Abstract reports main effects, not a vitamin-E-added bleeding estimate.
How this applies: Separates aspirin main-effect bleeding from an unproven vitamin E interaction and provides no vitamin E prevention benefit.
Cannot quantify exact aspirin-plus-vitamin-E major bleeding risk; early stopping and open design; no combination-cell-specific result in abstract.
Source 4: government nutrient reference
ods.od.nih.gov · Source check Sep 10, 2026
Population: General nutrition and supplement users.
Describes differing natural and synthetic IU-to-mg relationships, high amounts in many vitamin-E-only supplements, and bleeding-related medication cautions.
How this applies: Formulation and caution context; not direct evidence of an aspirin-vitamin E effect.
Does not quantify added bleeding risk with aspirin or validate a universal safe cutpoint such as 400 IU.
Research assessment: · Open full citations ↗
Timing & monitoring
Evidence is insufficient for blanket vitamin E avoidance or a protective aspirin-vitamin E dosing interval.
- Exact scope
- Vitamin E supplements, with form and dose variation. with Oral aspirin regimens in supplied studies.
- Medication form and route
- oral aspirin; oral vitamin E supplements
- Timing or duration
- No timing study supplied.
What remains uncertain
- No separation trial or validated universal dose cutoff.
Factors that may matter: product formulation; dose; other causes of bleeding risk.
Read the supporting source summaries
Source 1: controlled volunteer study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 20 men and 27 women; three experimental groups of 12 and control group of 11.
Vitamin E plus aspirin was associated with highly significant lower platelet adhesion to collagen; aspirin alone did not affect that adhesion measure.
How this applies: Direct co-use platelet-function evidence, not a quantified clinical bleeding outcome.
Allocation and combination-group schedule incompletely described; surrogate platelet outcomes; no clinical bleeding estimate.
Source 2: double-blind randomized study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 100 patients with transient ischemic attacks, minor strokes, or residual ischemic neurologic deficits.
No significant difference in hemorrhagic-stroke incidence; both hemorrhagic strokes occurred in vitamin E recipients. Abstract calls results preliminary.
How this applies: Direct co-use clinical context but insufficient to quantify added bleeding risk or recommend vitamin E for prevention.
No numeric bleeding effect, ambiguous vitamin E mass/activity notation and form, and no validated general conversion from the reported notation.
Source 3: open randomized 2x2 factorial trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 4,495 people at cardiovascular risk; mean age 64.4 years.
Severe bleeding was 1.1% with aspirin versus 0.3% with no aspirin; vitamin E had no effect on prespecified endpoints. Abstract reports main effects, not a vitamin-E-added bleeding estimate.
How this applies: Separates aspirin main-effect bleeding from an unproven vitamin E interaction and provides no vitamin E prevention benefit.
Cannot quantify exact aspirin-plus-vitamin-E major bleeding risk; early stopping and open design; no combination-cell-specific result in abstract.
Source 4: government nutrient reference
ods.od.nih.gov · Source check Sep 10, 2026
Population: General nutrition and supplement users.
Describes differing natural and synthetic IU-to-mg relationships, high amounts in many vitamin-E-only supplements, and bleeding-related medication cautions.
How this applies: Formulation and caution context; not direct evidence of an aspirin-vitamin E effect.
Does not quantify added bleeding risk with aspirin or validate a universal safe cutpoint such as 400 IU.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Private package prepared without clinical approval or release. | |
| Research summary published |
Article revision: 2fa1bf66b88b6e5b
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.